Linaprazan is a small molecule drug. The usage of the INN stem '-prazan' in the name indicates that Linaprazan is a proton pump inhibitor, not dependent on acid activation. Linaprazan is under investigation in clinical trial NCT00206284 (A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients Without Erosive Esophagitis.). Linaprazan has a monoisotopic molecular weight of 366.21 Da.
Linaprazan, 10 mM in DMSOAZD 0865AZD 0865Linaprazan,AZD-0865,inhibit,Proton Pump,Inhibitor,AZD 08652,3-Dimethyl-8-[(2,6-dimethylbenzyl)amino]-6-[N-(2-hydroxyethyl)aminocarbonyl]imidazo[1,2-a]pyridineImidazo[1,2-a]pyridine-6-carboxamide, 8-[[(2,6-dimethylphenyl)methyl]amino]-N-(2-hydroxyethyl)-2,3-dimethyl-